American Eagle - The apparel retailer increased its dividend by 14 percent to 12.5 cents a share. Shares were largely unchanged in extended-hours trading.
Morgan Stanley - Deutsche Bank upgraded the financial giant to "buy" from "hold." Shares rose in extended-hours trading.
Splunk - The software company posted a loss of 6 cents a share, in line with projections, while revenue topped estimates by $3 million at $54 million. Meanwhile, the company handed in second-quarter revenue guidance that came in line with expectations. Shares slumped in extended-hours trading.
Krispy Kreme Doughnuts - The doughnut company reported earnings of 20 cents a share, excluding one-time items, on revenue of $121 million, beating forecasts for 17 cents a share on sales of $116 million. In addition, the company handed in full-year earnings guidance that exceeded current estimates. Shares rallied in extended-hours trading.
Guess - The clothing retailer posted earnings of 14 cents a share, easily beating expectations for 8 cents a share, while revenue was in line at $549 million. Shares soared in extended-hours trading.
Omnivision Technologies - The digital imaging products developer posted earnings of 56 cents a share, excluding one-time items, on sales of $336 million, exceeding Wall Street estimates for 21 cents a share on sales of $319 million. The company also handed in current-quarter earnings and sales outlook that were well above expectations. Shares shot higher after being temporarily halted in extended-hours trading.
Wells Fargo initiated coverage of CVS Caremark with an "outperform" rating. The brokerage started coverage of Catamaran and Express Scripts with a "market perform" recommendation. Shares of all three companies were mostly flat in extended-hours trading.
Jazz Pharmaceuticals - Stifel Nicolaus initiated coverage of the specialty pharmaceutical company with a "buy" rating and price target of $80 a share. Shares edged higher in extended-hours trading.
Valeant Pharmaceuticals - BMO Capital initiated coverage of the pharmaceutical company with an "outperform" rating and a price target of $107.